ZURICH (Reuters) – Swiss drugmaker Novartis said on Tuesday that a large British study of its cholesterol-lowering drug Leqvio is now not expected to be completed until 2026, a year later than expected,...
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok